Covis currently sells Alvesco, Omnaris and Zetonna in the US and will become the owner of the medicines. In return, it will pay AstraZeneca $350 million upon closing.
Sunovion has entered into a definitive agreement to divest the U.S. market rights to Sunovion’s ciclesonide products ALVESCO Inhalation Aerosol, OMNARIS Nasal Spray, and ZETONNA Nasal Aerosol to Covis Pharma. Ciclesonides are included in the corticosteroi